Loading…
Anhui-based pharmaceutical technology company; specific product line not established from available knowledge.
Anhui-based pharmaceutical technology company; specific product line not established from available knowledge.
Moat: none
Headquarters: Anhui, China · Employees: 376
Size Anhui Wanbang Pharmaceutical Technology (301520.SZ) is a China Health Care company (Biotechnology) with a market value of $803M, the 2752nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥57.80 on 6 Nov 2026.
Performance Over six months the shares gained 90.6%, against -19.9% for the median peer and -16.4% for the China market (cap-weighted) — 2nd highest of 19 in its peer set.
Growth Revenue fell 15.3% over the last twelve months (peer median +0.6%); the operating margin is -8.2% (peer median -61.7%).
Valuation It trades at 17.9× enterprise value to sales against a peer median of 8.2× (7th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 49% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +34 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.5 points below its cost of capital (6.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥249M | CN¥274M | CN¥378M | CN¥341M | CN¥260M |
| Revenue growth | — | -27% | +11% | +31% | — |
| Gross profit | CN¥62.1M | CN¥61.3M | CN¥139M | CN¥160M | CN¥128M |
| EBITDA | n/a | CN¥20.3M | CN¥68.8M | CN¥115M | CN¥104M |
| Net income | CN¥3.90M | CN¥36.4M | CN¥85.5M | CN¥108M | CN¥98.7M |
| Free cash flow | CN¥21.2M | -CN¥9.63M | CN¥26.2M | -CN¥11.7M | CN¥24.8M |
| Capital expenditure | CN¥3.79M | CN¥19.2M | CN¥41.8M | CN¥86.0M | CN¥50.7M |
| Total debt | CN¥1.96M | CN¥4.29M | CN¥1.60M | CN¥1.00M | CN¥29,884 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301520.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.8% | -7.4% | 7th lowest of 21 |
| 6-month return | +90.6% | -19.9% | 2nd highest of 19 |
| Distance from 52-week high | -35.0% | -44.9% | 5th highest of 21 |
| Revenue growth (TTM) | -15.3% | +0.6% | 7th lowest of 16 |
| Operating margin | -8.2% | -61.7% | 4th highest of 18 |
| EV / Sales | 17.9× | 8.2× | 7th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 48.8% | 8.8% | most demanding of 6 |
| Growth delivered (Del g) | +14.7% | +11.8% | 3rd highest of 6 |
| Hurdle (Req g minus delivered) | +34.2 pp | +6.4 pp | most demanding of 6 |
| ROIC minus cost of capital | -7.5 pp | -20.3 pp | 4th highest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $803M | +91% | -15% | -8% | 17.9× | 48.8% | +14.7% |
| R&G PharmaStudies 301333.SZ | China | $803M | -12% | +21% | 11% | 3.9× | 20.1% | +11.8% |
| Beijing SL Pharmaceutical 002038.SZ | China | $793M | -21% | -4% | -119% | 7.6× | -12.3% | -10.9% |
| Wuhan Keqian Biology 688526.SS | China | $814M | -19% | -22% | 20% | 4.7× | 8.8% | +2.4% |
| Alphamab Oncology 9966.HK | Hong Kong | $777M | -39% | -32% | -38% | 8.2× | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $777M | n/a | n/a | n/a | n/a | n/a | n/a |
| Prime Medicine PRME | United States | $843M | +45% | -18% | -4,825% | 211.3× | n/a | n/a |
| Peptidream 4587.T | Japan | $856M | -10% | +1% | -25% | 6.6× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $859M | -56% | +160% | -62% | 3.5× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $746M | -37% | +153% | -20% | 13.1× | 43.2% | +21.5% |
| MeiraGTx MGTX | United States | $864M | -8% | +948% | 46% | 2.1× | -9.9% | +39.2% |
| GNI 2160.T | Japan | $866M | -29% | +10% | -24% | 5.7× | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $726M | -16% | +4,564% | -92% | 43.1× | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $892M | -14% | +16% | -18% | 4.3× | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $902M | -45% | -84% | -633% | 11.1× | n/a | n/a |
| Sana Biotechnology SANA | United States | $709M | -32% | n/a | n/a | n/a | n/a | n/a |
| Inventiva IVA.PA | France | $912M | -29% | -100% | -307,063% | 14,560.9× | n/a | n/a |
| Solid Biosciences SLDB | United States | $707M | -9% | n/a | n/a | n/a | n/a | n/a |
| Odyssey Therapeutics ODTX | United States | $924M | n/a | -33% | -5,415% | 208.9× | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $697M | +744% | n/a | -4,975% | 625.6× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $927M | -54% | n/a | -108% | 26.5× | n/a | n/a |